



ASX ANNOUNCEMENT

21 DECEMBER 2023

CHIMERIC THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE AT JPM WEEK

Sydney, Australia, 21 December 2023: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that it is presenting at the Biotech Showcase 2024 being held in conjunction with JP Morgan week in San Francisco.

Date: Tuesday January 9, 2024
Time: 3:00 PM PST
Location: Yosemite C (Ballroom Level), Hilton San Francisco

“We are excited to once again be part of Biotech Showcase during JPM week,” said Jennifer Chow, Chief Executive Officer of Chimeric Therapeutics. “Biotech Showcase provides a unique opportunity for Chimeric to engage with potential investors and partners. We look forward to showcasing our platforms and recent progress and fostering collaborations and partnerships that may shape our future.”

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

“We are delighted that Chimeric Therapeutics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime opportunity for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric’s world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.



CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase 1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow

Chief Executive Officer and Managing Director
Chimeric Therapeutics

T: + 1 9087238387

E: jchow@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Paul Hopper

Executive Chairman
Chimeric Therapeutics

T: + 61 406 671 515

E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au